mbnl1

Phenylbutazone (Butazolidine) is a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis.

RNA binder 2 (Compound 20) serves as a covalent inhibitor of r(CUG)expRNA in myotonic dystrophy type 1 (DM1). It attaches to RNA through the Hoechst scaffold, hindering the binding of MBNL1 and reinstating the normal splicing process. This compound holds potential for research in the context of myotonic dystrophy type 1.

Lomofungin, a novel antibiotic produced by Streptomyces lomondensis sp. N, exhibits antimicrobial activity and inhibits the binding of MBNL1-CUG RNA. This compound has potential applications in targeting specific RNA-protein interactions.

Phenylbutazone-13C12 is the 13C12-labeled version of Phenylbutazone. Phenylbutazone (T1432) serves as an effective reducing cofactor for prostaglandin H synthase (PHS) peroxidase. It is recognized as a hepatotoxin and classified as a non-steroidal anti-inflammatory drug (NSAID). Additionally, Phenylbutazone (T1432) induces the expression of muscleblind-like protein 1 (MBNL1) and holds potential for research in ankylosing spondylitis.

Phenylbutazone (diphenyl-D10) is a deuterated form of Phenylbutazone. It serves as a reductive cofactor for prostaglandin H synthase (PHS) peroxidase and is classified as a hepatotoxin and a nonsteroidal anti-inflammatory drug (NSAID). Phenylbutazone (T1432) also induces the expression of muscleblind-like protein 1 (MBNL1) and shows potential for research in ankylosing spondylitis.